Literature DB >> 15331065

Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease.

Jayanta Choudhury1, Arun J Sanyal.   

Abstract

The prevalence of obesity has reached epidemic proportions in most of the western world. Current estimates suggest that 22.5%of the population of the United States suffers from obesity and is at risk for development of obesity-related complications, including hypertension, coronary artery disease, diabetes, hyperlipidemia,increased predisposition for various cancers, and nonalcoholic fatty liver disease. Fatty liver disease is currently the most common abnormality observed in hepatology practice. Since it was first reported in the 1980s in obese diabetic females, our understanding of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) has undergone significant metamorphosis. It is now universally accepted that insulin resistance and subsequent hyperinsulinemia are key factors that lead to both NAFL and NASH.This article reviews the role of insulin resistance in the genesis of these conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331065     DOI: 10.1016/j.cld.2004.04.006

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  32 in total

1.  The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial.

Authors:  William W Shields; K E Thompson; G A Grice; S A Harrison; W J Coyle
Journal:  Therap Adv Gastroenterol       Date:  2009-05       Impact factor: 4.409

Review 2.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 3.  Management of NAFLD: a stage-based approach.

Authors:  Mary E Rinella; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

4.  Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients.

Authors:  A C Gupta; A K Chaudhory; C Pande; P Sakhuja; Y Singh; S F Basir; S K Sarin
Journal:  Hepatol Int       Date:  2010-12-01       Impact factor: 6.047

Review 5.  Nonalcoholic fatty liver disease.

Authors:  Leon A Adams; Paul Angulo; Keith D Lindor
Journal:  CMAJ       Date:  2005-03-29       Impact factor: 8.262

Review 6.  The role of lifestyle changes in the management of chronic liver disease.

Authors:  Valerio Nobili; Christine Carter-Kent; Ariel E Feldstein
Journal:  BMC Med       Date:  2011-06-06       Impact factor: 8.775

7.  Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease.

Authors:  Zhigang Wang; Tong Yao; Maria Pini; Zhanxiang Zhou; Giamila Fantuzzi; Zhenyuan Song
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-04       Impact factor: 4.052

8.  Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development.

Authors:  Jian-Ping Liu; Wen-Li Zou; Shui-Jiao Chen; Hong-Yun Wei; Ya-Ni Yin; Yi-You Zou; Fang-Gen Lu
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice.

Authors:  Chih-Wen Lin; Hao Zhang; Min Li; Xiwen Xiong; Xi Chen; Xiaoyun Chen; Xiaocheng C Dong; Xiao-Ming Yin
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

Review 10.  Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment.

Authors:  Tim C M A Schreuder; Bart J Verwer; Carin M J van Nieuwkerk; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.